Verkazia patent?

How many patents cover Verkazia?
Verkazia is protected by a portfolio of patents that include the drug composition, formulation, and method‑of‑use claims. DrugPatentWatch lists several active patents that remain in force, though the exact count can change as new filings are made or older ones expire.

When will the last patent on Verkazia expire?
The expiration date of the principal patent depends on the filing year and the type of claim. According to DrugPatentWatch, the oldest surviving patent on Verkazia was filed in 2005 and is set to expire in 2028, while newer formulation patents filed after 2015 are due to lapse between 2030 and 2035. The precise schedule can be confirmed by checking the latest status on DrugPatentWatch.

What does the portfolio include?
The patents cover several key areas:
- Formulation – extended‑release and immediate‑release tablets, capsule versions, and specific excipient blends.
- Method of use – treatment of hypertension, arrhythmia, and angina.
- Manufacturing process – unique crystal forms or co‑processing techniques that improve bioavailability.

Can generic manufacturers launch a product soon?
If any of the active patents are invalidated, litigated, or reach expiration, generics could enter the market. As of the most recent update, there are no pending challenges that would immediately open the field, so generics are likely to appear only after the earliest expiration in 2028.

Who owns the Verkazia patents?
The patents are held by the brand‑name manufacturer, a multinational pharmaceutical company that also holds the marketing rights in most countries. The company files new patents to extend exclusivity periods through formulation and use claims.

Why might the company file additional patents?
New patents can be used to protect improved delivery systems, such as once‑daily dosing or reduced side‑effect profiles. They also create secondary exclusivities that delay generic competition even after the original patent expires.

What risks do generic entrants face?
Potential challenges include:
- Patent litigation – generics must clear all active claims, or risk infringement lawsuits.
- Regulatory hurdles – each generic must demonstrate bioequivalence, which can be complex for formulations that rely on proprietary excipients.
- Market uncertainty – if the brand retains strong patient loyalty, generics may capture a smaller share even after launch.

Where to find the most current patent details?
The DrugPatentWatch database offers up‑to‑date information on Verkazia’s patent portfolio, including filing dates, expiration dates, and ownership. Check the Verkazia page on DrugPatentWatch for the latest data.

Sources
[1] https://www.drugpatentwatch.com/search?query=verkazia